Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...7273747576777879808182...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    Clinical, Journal:  Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer. (Pubmed Central) -  Oct 8, 2020   
    However, combining the EGFR inhibitor cetuximab, the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improves overall survival. This review discusses the current treatment field for patients with BRAFV600E mutant metastatic CRC and summarizes the pharmacology, efficacy and safety of the novel doublet and triplet therapies consisting of encorafenib and cetuximab with or without binimetinib.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. (Pubmed Central) -  Oct 7, 2020   
    Similarly, the modification of classical ADCs has resulted in the first, fully recombinant versions. In this review, we discuss significant advancements in EGFR-targeting immunoconjugates, including ITs and recombinant photoactivable ADCs, which serve as a blueprint for further developments in the evolving domain of cancer immunotherapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Claims DATA Analysis of Patients with Metastatic Colorectal Cancer (MCRC) in Germany () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1813;    
    According to our analysis, outpatient treatment in the period 2016 consisted of more traditional regimes, whereas the extent of targeted therapies with mAb was limited. Additionally, the transition to de-escalating maintenance therapy as recommended in guidelines was applied for only a few patients.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
    Review, Journal, IO Biomarker:  BRAF V600E-mutant colorectal cancers: Where are we? (Pubmed Central) -  Oct 3, 2020   
    In the second or third line, the triplet encorafenib, binimetinib and cetuximab, as well as the doublet encorafenib and cetuximab are superior to the association of irinotecan plus cetuximab in terms of response and survival (phase III study BEACON) and represent a new therapeutic standard. Their use on the front line is under study.
  • ||||||||||  albumin-bound paclitaxel / Generic mfg.
    Trial completion, Trial completion date, Metastases:  Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer (clinicaltrials.gov) -  Sep 30, 2020   
    P2,  N=30, Completed, 
    Our findings also suggest a correlation between DSG3 and EGFR in OSCC, and this affects cetuximab treatment efficacy. Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Oct 2019
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Rare case of acquired perforating dermatosis induced by cetuximab. (Pubmed Central) -  Sep 27, 2020   
    A phase 2 study (NCT03254927) has been initiated to evaluate CDX-3379 in combination with cetuximab for patients with advanced HNSCC. No abstract available
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  PRSS contributes to cetuximab resistance in colorectal cancer. (Pubmed Central) -  Sep 26, 2020   
    PRSS expression in monoclonal antibody (mAb)-treated patients with cancer from The Cancer Genome Atlas database was also evaluated to determine whether patients with higher PRSS expression have significantly reduced progression-free survival. Our work provides a strong scientific rationale for targeting PRSS in combination with cetuximab therapy.
  • ||||||||||  fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO Biomarker:  Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (Pubmed Central) -  Sep 26, 2020   
    Finally, the first line conquest is acquired since the final results of the keynote-048 phase III study that demonstrated the superiority of pembrolizumab versus EXTREME in CPS ≥ 1 patients, and with the addition of platinum and 5FU in all patients...Further progress needs the use of new immunotherapeutic agents such as monalizumab or ICOS agonist rather in combination with an anti-PD(L)1...Finally, ICIs has to be studied in the locally advanced setting where there is a chance of cure. Several trials are testing the potential synergistic combination of ICIs with radiotherapy and platinum or cetuximab, or ICIs used in a neoadjuvant setting.
  • ||||||||||  Journal:  Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. (Pubmed Central) -  Sep 25, 2020   
    Modern immunotherapy with immunomodulating antibodies, dubbed immune checkpoint inhibitors, such as anti-programmed cell death protein-1 (anti-PD-1) inhibitors nivolumab and pembrolizumab, showed unprecedented activity in one first-line (KEYNOTE-048) and several second-line trials (CheckMate-141, KEYNOTE-012, KEYNOTE-055, and KEYNOTE-040)...In oligometastatic disease, emerging data indicate long-term benefit with locally ablative techniques including metastasectomy and stereotactic radiotherapy of pulmonary but also hepatic and other distant lesions. In the frame of highly-individualized cancer care, a particularly intriguing approach is a combination of systemic and local therapies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    [VIRTUAL] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study) (Channel 1) -  Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_261;    
    P3
    In BEACON CRC study,triplet therapy encorafenib + binimetinib + cetuximab and doublet therapy with encorafenib + cetuximab demonstrated improved overall survival (OS) and objective response in patients with BRAF V600E mCRC compared with current standard of care (median OS: 9.3 months (m) [triplet] and 9.3 m [doublet] vs 5.9 m [control]; ORR:27% [triplet] 20% [doublet] vs 2% [control], p<0.0001 for both)...Methods BEACON CRC is a randomized, 3-arm, Ph 3 study evaluating triplet (n=224) or doublet (n=220) regimens vs investigator’s choice of irinotecan or FOLFIRI + cetuximab (n=221) in patients (pts) with BRAF V600E-mutated mCRC...Funding: Pfizer. Clinical trial identification: NCT02928224.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, IO Biomarker:  Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. (Pubmed Central) -  Sep 24, 2020   
    These data support the potential therapeutic of cetuximab in KRAS mutated mCRC carrying non-functional receptor KIR2DS4 since these patients significantly prolong their OS even after heavily treatment. KIR2DS4 typing could be used as predictive marker for identifying RAS mutated patients that could benefit from combination approaches of anti-EGFR monoclonal antibodies and other immunotherapies to overcome the resistance mediated by mutation in RAS.
  • ||||||||||  metformin / Generic mfg., Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Journal, Tumor microenvironment:  Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics. (Pubmed Central) -  Sep 24, 2020   
    However, while immuno-oncology agents are rapidly expanding, the role that the immune system plays in the mechanism of action and clinical efficacy of standard conventional therapies is likely underappreciated. In this article, we focus on how conventional and targeted therapies may directly modulate the immune system and the tumor microenvironment to better understand the effects and combinatorial potential of these therapies in the context and era of immunotherapy.
  • ||||||||||  fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic AgS quantum dots. (Pubmed Central) -  Sep 24, 2020   
    Interestingly, while treatment of cells with free 5FU activated autophagy, a cellular mechanism conferring resistance to cell death, these EGFR targeting multimodal QDs significantly overcame drug resistance compared to 5FU treatment alone. The improved therapeutic outcome of 5FU delivered to A549 cells by Cet conjugated Ag2S QDs is suggested as the synergistic outcome of enhanced receptor mediated uptake of nanoparticles, and hence the drug, coupled with suppressed autophagy even in the absence of addition of an autophagy suppressor.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells. (Pubmed Central) -  Sep 23, 2020   
    Overexpression of DAB2IP decreases the Ras activity, inhibits cell proliferation, and increases sensitivity to cetuximab in wild-type pancreatic cancer cells. In conclusion, DAB2IP may serve as a potential molecular therapeutic target for the treatment of pancreatic cancer.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Review, Journal:  Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer. (Pubmed Central) -  Sep 23, 2020   
    The role of adjuvant chemotherapy in patients with high-risk stage II and patients with stage III disease is examined, along with the role on circulating tumor DNA (ctDNA) as well as with the biologic targeted agents cetuximab and bevacizumab. Lastly, the authors detail the postoperative surveillance schedules after surgical resection with respect to survival outcomes.